CN107184977A - 急性淋巴细胞白血病的治疗方法 - Google Patents

急性淋巴细胞白血病的治疗方法 Download PDF

Info

Publication number
CN107184977A
CN107184977A CN201710366308.1A CN201710366308A CN107184977A CN 107184977 A CN107184977 A CN 107184977A CN 201710366308 A CN201710366308 A CN 201710366308A CN 107184977 A CN107184977 A CN 107184977A
Authority
CN
China
Prior art keywords
patient
mrd
cd19xcd3
blinatumomab
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710366308.1A
Other languages
English (en)
Chinese (zh)
Inventor
格哈德·祖格迈尔
伊夫林·德根哈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41692882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107184977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of CN107184977A publication Critical patent/CN107184977A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201710366308.1A 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法 Pending CN107184977A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
CN2009801443998A CN102209728A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801443998A Division CN102209728A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Publications (1)

Publication Number Publication Date
CN107184977A true CN107184977A (zh) 2017-09-22

Family

ID=41692882

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710366308.1A Pending CN107184977A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法
CN2009801443998A Pending CN102209728A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801443998A Pending CN102209728A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Country Status (26)

Country Link
US (3) US20130323247A1 (https=)
EP (2) EP2982696B1 (https=)
JP (2) JP5647132B2 (https=)
KR (1) KR101695327B1 (https=)
CN (2) CN107184977A (https=)
AU (4) AU2009313040B2 (https=)
BR (1) BRPI0921482B1 (https=)
CA (1) CA2742249C (https=)
CY (2) CY1117033T1 (https=)
DK (2) DK2342227T3 (https=)
ES (2) ES2727585T3 (https=)
HR (2) HRP20151168T1 (https=)
HU (2) HUE043326T2 (https=)
IL (1) IL212652A (https=)
LT (1) LT2982696T (https=)
ME (2) ME02363B (https=)
MX (1) MX2011002927A (https=)
NZ (1) NZ591311A (https=)
PL (2) PL2982696T3 (https=)
PT (2) PT2342227E (https=)
RS (2) RS54456B1 (https=)
RU (1) RU2536940C2 (https=)
SI (2) SI2982696T1 (https=)
SM (2) SMT201900278T1 (https=)
WO (1) WO2010052014A1 (https=)
ZA (1) ZA201103255B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020135335A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US11013800B2 (en) 2011-05-16 2021-05-25 Evive Biotech Ltd. Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1976886T3 (en) * 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
PT2342227E (pt) * 2008-11-07 2015-11-13 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda
CN107227335A (zh) 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
NZ609201A (en) * 2010-10-27 2015-01-30 Amgen Res Munich Gmbh Means and methods for treating dlbcl
CN103533943B (zh) * 2010-11-10 2018-02-13 安进研发（慕尼黑）股份有限公司 由cd3特异性结合结构域导致的不良作用的预防
KR102345943B1 (ko) * 2011-04-28 2021-12-31 암젠 리서치 (뮌헨) 게엠베하 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2715679T3 (es) 2014-05-30 2019-06-05 Amgen Res Munich Gmbh Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
WO2016109549A1 (en) 2014-12-30 2016-07-07 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
AU2016222830B2 (en) 2015-02-24 2021-02-25 Bioatla Llc Conditionally active biological proteins
CN107995913B (zh) * 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
RS66511B1 (sr) 2015-05-20 2025-03-31 Amgen Res Munich Gmbh Deplecija b ćelija kao dijagnostički marker
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR20250111232A (ko) * 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
MX2021014644A (es) * 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250282864A1 (en) 2021-10-15 2025-09-11 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engagers
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299410A (zh) * 1998-04-21 2001-06-13 麦克美特(显微医学)生物医学研究有限公司 CD19xCD3特异性多肽及其用途
CN1795208A (zh) * 2003-05-31 2006-06-28 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
DK1976886T3 (en) * 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PT2342227E (pt) * 2008-11-07 2015-11-13 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282128B (zh) * 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
MX2011012632A (es) * 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299410A (zh) * 1998-04-21 2001-06-13 麦克美特(显微医学)生物医学研究有限公司 CD19xCD3特异性多肽及其用途
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
CN1795208A (zh) * 2003-05-31 2006-06-28 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HTTP://CLINICALTRIALS.GOV/CT2/SHOW/NCT00560794?TERM=NCT00560794&: "phase II study of the BiTE blinatumomab in patients with minimal residual disease of B-precursor acute lymphoblastic leukemia(ALL)", 《CLINICALTRIALS.GOV》 *
M CSÓKA ET AL.: "Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody", 《LEUKEMIA》 *
RALF BARGOU ET AL.: "Tumor regression in cancer patients by very low doses of a T cell–engaging antibody", 《SCIENCE》 *
刘世和等: "Ph染色体阳性成人急性淋巴细胞白血病患者预后相关因素分析", 《中华血液学杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013800B2 (en) 2011-05-16 2021-05-25 Evive Biotech Ltd. Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020135335A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US12577305B2 (en) 2018-12-24 2026-03-17 Itabmed (Hk) Limited Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof

Also Published As

Publication number Publication date
PL2982696T3 (pl) 2019-08-30
CY1122366T1 (el) 2021-01-27
PL2342227T3 (pl) 2016-04-29
JP2015057417A (ja) 2015-03-26
DK2342227T3 (en) 2016-02-15
ES2727585T3 (es) 2019-10-17
EP2982696B1 (en) 2019-03-27
IL212652A0 (en) 2011-07-31
RS58827B1 (sr) 2019-07-31
PT2342227E (pt) 2015-11-13
WO2010052014A1 (en) 2010-05-14
AU2018260815A1 (en) 2018-11-22
ES2558434T3 (es) 2016-02-04
SMT201500328B (it) 2016-02-25
HUE043326T2 (hu) 2019-08-28
HK1220705A1 (en) 2017-05-12
HK1158668A1 (en) 2012-07-20
US20240109964A1 (en) 2024-04-04
JP2012508164A (ja) 2012-04-05
MX2011002927A (es) 2011-04-11
BRPI0921482A8 (pt) 2017-07-11
LT2982696T (lt) 2019-06-10
JP5647132B2 (ja) 2014-12-24
US20130323247A1 (en) 2013-12-05
EP2982696A3 (en) 2016-02-17
RU2011122819A (ru) 2012-12-20
PT2982696T (pt) 2019-06-04
KR101695327B1 (ko) 2017-01-11
CY1117033T1 (el) 2017-04-05
SI2342227T1 (sl) 2015-12-31
CA2742249A1 (en) 2010-05-14
BRPI0921482B1 (pt) 2022-09-20
CN102209728A (zh) 2011-10-05
AU2009313040B2 (en) 2015-07-09
IL212652A (en) 2015-05-31
AU2018260815B2 (en) 2020-03-05
RU2536940C2 (ru) 2014-12-27
HUE028175T2 (en) 2016-12-28
US20190300609A1 (en) 2019-10-03
AU2015238784A1 (en) 2015-10-29
HRP20190912T1 (hr) 2019-07-26
RS54456B1 (sr) 2016-06-30
NZ591311A (en) 2012-10-26
US11597766B2 (en) 2023-03-07
SMT201900278T1 (it) 2019-07-11
AU2017219083B2 (en) 2018-08-09
EP2342227A1 (en) 2011-07-13
AU2009313040A1 (en) 2010-05-14
KR20110091668A (ko) 2011-08-12
EP2982696A2 (en) 2016-02-10
EP2342227B1 (en) 2015-10-07
JP5955921B2 (ja) 2016-07-20
ZA201103255B (en) 2013-12-23
HRP20151168T1 (hr) 2015-12-04
BRPI0921482A2 (pt) 2016-01-12
ME02363B (me) 2016-06-20
CA2742249C (en) 2020-07-21
ME03480B (me) 2020-01-20
SI2982696T1 (sl) 2019-06-28
DK2982696T3 (da) 2019-05-27
AU2017219083A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
CN107184977A (zh) 急性淋巴细胞白血病的治疗方法
DK2344539T3 (en) Treatment of pediatric acute lymphoblastic leukemia
AU2020222239B2 (en) Car T-cells for the treatment of CD1a-positive cancer
CN101516394A (zh) 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途
CN101331151A (zh) 治疗肿瘤性疾病的方式和方法
HK40116152A (zh) 用於治疗cd1a阳性癌症的car t细胞
AU2022365121A1 (en) Methods of suppressing microglial activation
HK1220705B (en) Treatment of acute lymphoblastic leukemia
HK1158668B (en) Treatment of acute lymphoblastic leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination